The EXTEND trial was a double blind randomized placebo controlled study designed to test the effect of IL-6 receptor blockade (tocilizumab) in pediatric participants (age 6-17 years) with new onset type 1 diabetes. IL-6 pathway blockade is an effective immunotherapy in some autoimmune diseases including juvenile idiopathic arthritis and rheumatoid arthritis working, at
|
The Immune Tolerance Network (ITN) is a collaborative network for clinical research, funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The ITN, headquartered at the Benaroya Research Institute (BRI) in Seattle WA, has major operations centers at BRI and in San Francisco at University of California San Francisco (UCSF). This is a UCSF position |
Christian P. Larsen, M.D., D.Phil., the Immune Tolerance Network’s (ITN’s) deputy director in transplantation, transplant surgeon, and immunologist was presented with the 2021 American Medical Association (AMA) Scientific Achievement Award.
The PAUSE trial was conducted to determine whether blocking CD28/B7 costimulatory signaling with abatacept would prevent relapse of psoriasis after effective treatment with ustekinumab (an IL12/23 antagonist).
In an article published today in Frontiers in Immunology, Immune Tolerance Network (ITN) leadership and clinical trial physicians review ITN's approach to the development of therapies that aim to establish tolerance in immune mediated diseases.
In a study published on April 22, 2020 in JACI, data from ITN’s CATEEC clinical trial was used to investigate the connection between asthma and allergic disease and the novel coronavirus, SARS-
The ITN article that reported the results of the CATEEC clinical trial, which compared clinical and biological responses to cat allergen exposure by nasal allergen challenge (NAC) or environmental exposure chamber (EEC) was selected to be an Editors’ Choice feature and was displayed on the American Academy of Allergy Asthma & Immunology (AAAAI) website.
The first patient first visit (FPFV) has occurred for ITN’s REBOOT clinical trial. REBOOT is a clinical study that aims to evaluate the safety and effectiveness of belimumab and intravenous rituximab at inducing remission of primary membranous nephropathy (MN) compared to rituximab alone.
The Immune Tolerance Network (ITN) has opened the BEAT-MS clinical trial for enrollment. BEAT-MS or “Best Available Therapy vs. Autologous Hematopoietic Stem Cell Transplant (AHSCT) for MS” will investigate high dose immunosuppression followed by AHSCT – a type of transplant using a patient’s own immune stem cells – compared to the best medical treatment currently available for multiple sclerosis (MS) in participants with relapsing MS.
This week in the article “How to Prevent Food Allergies,” Scientific American discusses the changes over the years to medical advice regarding children and dietary allergens. The article notes the results of the Immune Tolerance Network’s (ITN’s) LEAP (Learning Early About Peanut Allergy) Study that prompted the change in the American Academy of Pediatrics (AAP) guidance.